Background: We examined the detection of low-level viraemia at week 24 as a predictor of sustained virological response (SVR) and viral relapse/breakthrough, and the agreement between the Roche Cobas TaqMan™ HCV RNA assay (TaqMan) and Roche Cobas® Amplicor HCV qualitative assay (Amplicor; both Roche Molecular Diagnostics, Pleasanton, CA, USA) for detection of lowlevel viraemia. Methods: A total of 871 treatment-naive HCV genotype 1 patients participating in an induction-dose pegylated interferon therapy study had virological responses assessed using TaqMan. A total of 151 patients with HCV RNA levels ≤500 IU/ml had samples tested in parallel using the Amplicor and TaqMan assays. Results: SVR was significantly lower and relapse/breakthrough significantly higher in patients with low-level residual viraemia at week 24 compared with those who had undetectable viraemia: SVR was 72%, 29% and 14% (P<0.0001) and relapse/breakthrough 28%, 71% and 86% (P<0.0001) in patients with viraemia that was undetectable, detectable <15 IU/ml and detectable 15-<50 IU/ml, respectively, at week 24. The negative predictive value (NPV) for a week-24 virological response for SVR was 86%, 90% and 90% using TaqMan cutoffs of undetectable, <15 IU/ml and <50 IU/ml, respectively. The percentage agreement between Amplicor and TaqMan was similarly high for TaqMan cutoffs of 50 IU/ml and 15 IU/ml, but lower for undetectable viraemia (83%, 83% and 70%, respectively). Conclusions: These data emphasize the importance of achieving undetectable HCV RNA during pegylated interferon therapy to maximize SVR; however, the current 24-week stopping rule of undetectable HCV RNA appears too stringent when using sensitive PCR assays given the observed lower NPV for SVR using the TaqMan undetectable cutoff. Our data also suggest that a TaqMan <15 IU/ml result is comparable to an Amplicornegative result (that is, below the assay cutoff value) when monitoring viral response.
Response-guided therapy involving the individualization of therapy based on early virological responses (EVRs) during treatment has become the standard of care for patients with chronic hepatitis C treated with pegylated interferon (PEG-IFN) plus ribavirin (RBV). Indeed, all major published practice guidelines include stopping rules based on the positive predictive values (PPVs) and negative predictive values (NPVs) of virological responses
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Introduction at different time points during the first 24 weeks of treatment for prediction of sustained virological response (SVR) [1, 2] . These include the achievement of an EVR, defined as at least a 2 log 10 reduction in HCV RNA or HCV-RNA-negative at week 12 as the primary demarcation point for ongoing therapy [3] [4] [5] [6] . In addition, patients who achieve an EVR but who have detectable HCV RNA at week 24 are recommended to cease treatment at that time because of futility of response [1, 2] . Such stopping rules, however, are critically dependent on the sensitivity of the test used to measure virological response.
Until recently the Roche Cobas ® Amplicor HCV qualitative assay (Amplicor; Roche Molecular Diagnostics, Pleasanton, CA, USA) with a lower limit of detection (LOD) of 50 IU/ml has been the most widely used test available for HCV RNA monitoring during HCV treatment [7, 8] . Using HCV RNA measurements from this assay, studies have shown that a significant proportion of patients who achieve a virological response on-treatment subsequently relapse after treatment discontinuation [9, 10] . Thus, there is a need to further optimize response-guided therapy via the improved prediction of SVR and/or virological relapse in order to improve treatment outcomes. In this context, recent studies utilizing sensitive transcription-mediated amplification (TMA) and real-time PCR HCV RNA assays indicate that residual viraemia at the end of therapy can predict virological relapse following treatment [11, 12] .
PCR assays in real-time platforms are quantitative assays that provide greater sensitivity and lower LOD for the measurement of HCV RNA in the order of 10-15 IU/ ml. These assays can be fully automated, have an excellent dynamic range and do not yield false-positive results due to carryover contaminations. Real-time PCR has become the technique of choice to detect and quantify viral genomes in clinical practice [13] . The Cobas TaqMan™ HCV RNA assay (TaqMan; Roche Molecular Diagnostics) is one such assay that, coupled with automated extraction in Cobas Ampliprep (Roche Molecular Diagnostics), allows HCV RNA quantification down to 15 IU/ml, and below this limit it reports either undetectable or detectable HCV RNA [14] [15] [16] . Another is the highly sensitive Abbott RealTime HCV RNA assay (Abbott Molecular, Inc., Des Plaines, IL, USA), which has a lower LOD of 12 IU/ml and slightly better dynamic range for HCV RNA quantification than the TaqMan assay [12, [16] [17] [18] . Both of these assays have been shown to be highly effective in predicting SVR to PEG-IFN plus RBV in chronic HCV patients [12, 18] , although variation might exist between assays in the predictability of SVR to PEG-IFN-based therapy. In addition, differences have also been reported in the sensitivity of the TaqMan assay to detect different HCV genotypes [19, 20] ; therefore, it is important that the same detection assay is used to monitor HCV RNA during antiviral therapy.
We therefore aimed to assess the utility of a sensitive real-time HCV RNA detection assay for on-treatment clinical guidance in patients with chronic HCV genotype 1 infection, undergoing PEG-IFN plus RBV therapy. Specifically, we examined the detection of residual viraemia as a predictor of relapse by the TaqMan assay at week 24 in the CHARIOT study. In addition, we examined the agreement between the TaqMan assay (LOD 15 IU/ml) and the Amplicor assay (LOD 50 IU/ml) for detection of low-level viraemia.
Methods
The CHARIOT trial methods and patient population have previously been described in detail [21] . Briefly, CHARIOT was a multicentre, multinational, randomized open-label active controlled study evaluating the safety and efficacy of high-dose PEG-IFN-α2a (360 mg/week) induction therapy for the first 12 weeks versus standard PEG-IFN-α2a (180 mg/week), both in combination with standard-dose RBV in treatment-naive chronic genotype 1 patients. Study recruitment commenced through a network of Australian sites in August 2004 and expanded from mid-2006 to several other countries including New Zealand, Thailand, Canada, Mexico and Argentina. Eligible participants included treatment-naive adults aged 18-75 years with serological evidence of HCV genotype 1 infection (repeatedly anti-HCV-positive and/or HCV-RNA-positive), quantifiable serum HCV RNA>600 IU/ml (TaqMan assay; Roche Molecular Diagnostics) and compensated liver disease. A total of 896 patients were enrolled into the study between September 2004 and February 2007 and randomly assigned 1:1 to induction (448 patients) and standard (448 patients) therapy groups; 871 patients formed the intention-to-treat analysis population.
Assessments and efficacy end points
Clinical and laboratory safety and efficacy assessments were performed during the treatment period every 4 to 6 weeks through to week 48, and after 4, 12 and 24 weeks (week 72) of follow-up. Quantitative serum/plasma HCV RNA levels were measured at baseline and at weeks 4, 8, 12, 24, 48 and 72. HCV RNA assessments were performed by two central laboratories (SEALS, Prince of Wales Hospital, Sydney, Australia and Cenetron Diagnostics, Austin, TX, USA) using the TaqMan assay coupled with automated extraction in Cobas Ampliprep (LOD 15 IU/ml, linear range 43-69×10 6 IU/ml; detects HCV genotypes 1-6). The TaqMan assessment platforms from both laboratories were validated and results from SEALS and Cenetron agreed in the assessment of an external Acrometrix OptiQuant HCV-RNA panel (Life Technologies Co., Benicia, CA, USA). HCV virological efficacy end points based on undetectable HCV RNA, including the primary end point at week 72, were based on TaqMan levels <15 IU/ml (including both undetectable and detectable viraemia <15 IU/ml).
The primary efficacy end point was SVR, defined as undetectable or <15 IU/ml HCV RNA in serum at week 72. Patients with detectable HCV RNA and <2 log 10 decrease in HCV RNA level at week 12 were encouraged to continue therapy up until week 24; however, those with detectable HCV RNA at week 24 were required to discontinue study therapy at that time.
Evaluation of week 24 low-level HCV viraemia
Initial versions of the protocol relied on local laboratory results for clinical decision making at week 24 using the Amplicor assay. Subsequently, the protocol was amended and clinical decisions were based on realtime HCV RNA TaqMan assessments from the central laboratories. To maintain consistency throughout the study, patients with a TaqMan result at week 24 falling within the 15-155 IU/ml range (calculated using the standard deviation of the TaqMan assay to ensure a 95% confidence interval [CI]) were also assessed with the Amplicor assay. The result of the Amplicor assay was used for decision-making regarding treatment continuation with a waiver granted to continue treatment to patients who were positive on TaqMan but negative on the Amplicor assay. Patients with detectable results on both TaqMan and Amplicor assays were required to discontinue treatment.
The effect of week-24 low-level HCV viraemia on HCV treatment response was evaluated by comparing the percentages of SVR and relapse/breakthrough in groups according to different HCV RNA cutoffs (TaqMan undetectable, <15 IU/ml and <50 IU/ml) and mutually exclusive HCV RNA strata (TaqMan undetectable, detectable <15 IU/ml and 15-<50 IU/ml; Figure 1A ). Relapse/breakthrough was defined as any patient who developed HCV RNA>15 IU/ml at week 72 after having a week 24 virological response. Relapse was defined as HCV RNA>15 IU/ml after an end-of-therapy response, and breakthrough as detectable HCV RNA>15 IU/ml at the end of therapy after a week 24 response.
Comparison of Amplicor and TaqMan assays for detection of residual viraemia
A total of 148 plasma and 3 serum samples from week 24 of treatment having TaqMan-based HCV RNA levels from <500 IU/ml to undetectable were tested in parallel on the TaqMan and Amplicor assays. Plasma samples stored at -70°C were thawed once only and testing was run in parallel with the Amplicor and the TaqMan assays according to manufacturer's instructions, in order to ensure identical conditions. Agreement was assessed between the Amplicor and TaqMan assays for specific RNA cutoffs (that is, undetectable, 15 IU/ml and 50 IU/ml) as determined by TaqMan. Agreement was defined as positive (that is, detectable) by Amplicor and positive (that is, detectable or ≥ the specified HCV RNA cutoff) by TaqMan; and negative (that is, undetectable) by Amplicor and negative (that is, undetectable or < the specified HCV RNA cutoff) by TaqMan.
Statistical analysis
Clopper-Pearson interval was calculated as the exact 95% CI for the response. Testing the null hypothesis that being a responder or non-responder at week 72 is independent from the values of HCV RNA at week 24 (undetectable, <15 or 15-<50) was carried out with the Pearson's χ 2 test of independence. The level of agreement between two assay methods was expressed as a percentage with 95% CI.
Results

Effect of residual viraemia on SVR
In the study population, 563 of 871 (65%) patients were virological responders at treatment week 24 as defined by undetectable HCV RNA by TaqMan. The proportion of patients responding at week 24 increased from 65% to 71% (622/871) and 72% (629/871) when higher HCV RNA cutoffs (<15 IU/ml and <50 IU/ml, respectively) were used to define virological response ( Figure 1A ). In addition to the 563 patients with undetectable HCV RNA at week 24, 66 (7.6%) patients had low-level residual viraemia (<50 IU/ml) at week 24; 61 (92.4%) of these had achieved an EVR at week 12. The 66 patients with low-level residual viraemia included 59 (6.8%) with detectable HCV RNA<15 IU/ml and 7 (0.8%) with HCV RNA levels 15-49 IU/ml. Of note, SVR was significantly lower in patients with low-level viraemia compared with those with undetectable HCV RNA (P<0.0001; Table 1 and Figure 1A ). By comparison, of the 151 patients who had Amplicor testing at 24 weeks, 75 of 116 (65%) who were Amplicor-negative (that is, below the assay cutoff value) at 24 weeks achieved an SVR ( Figure 1A ).
Effect of residual viraemia on predictive value of week 24 viral response
Virological response at week 24 was evaluated as HCV RNA undetectable, HCV RNA<15 IU/ml and HCV RNA<50 IU/ml (Table 2 and Figure 1A) . The PPVs of a week 24 virological response for SVR were 72% for TaqMan undetectable, 68% for TaqMan <15 IU/ml and 68% for TaqMan <50 IU/ml. The NPVs of a week 24 virological response for SVR were 86%, 90% and 90% for TaqMan undetectable, <15 IU/ml and <50 IU/ml, respectively (Table 2 and Figure 1A ). In comparison, the corresponding PPV and NPV for SVR for a week TaqMan (+) were Amplicor (-)
TaqMan undetectable TaqMan <15 IU/ml
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TaqMan <50 IU/ml 24 virological response of Amplicor-negative was 65% and 89%, respectively ( Figure 1A ). Figure 1A ). Among non-SVR patients at week 72, the breakdown in the proportion with relapse and breakthrough was equivalent between groups with HCV RNA undetectable and detectable <15 IU/ml at week 24; the frequency of relapse and breakthrough was 88% and 12%, respectively, for both HCV RNA undetectable and detectable <15 IU/ml (Table 1) .
Effect of residual viraemia on virological relapse/ breakthrough
Residual viraemia results using the Amplicor and TaqMan assays
A total of 151 samples were used to evaluate the agreement between TaqMan and Amplicor assays, including 72 with HCV RNA undetectable, 57 with detectable <15 IU/ml, 7 with 15-49 IU/ml and 15 with 50-<500 IU/ml. The overall percentage agreement between the TaqMan quantitative and Amplicor qualitative HCV RNA assays at week 24 was similarly high for HCV RNA cutoffs of 15 IU/ml and 50 IU/ml, but slightly lower for HCV RNA undetectable (83%, 83% and 70%, respectively; Table 3 ). Although all samples with undetectable HCV RNA by TaqMan were Amplicor-negative, 19 of the 57 (33%) with minimal residual viraemia <15 IU/ml and 3 of the 7 with 15-49 IU/ml were Amplicor-positive (that is, at or above the assay cutoff value). When this data was analysed according to HCV RNA cutoffs, 15-16% of the TaqMan-negative (that is, below the cutoff value) samples were Amplicor-positive at cutoffs of <15 IU/ ml and <50 IU/ml (Table 3 ; Figure 1B ). In addition, a high percentage of TaqMan-positive (that is, at or above the cutoff value) samples were Amplicor-negative across all three cutoffs evaluated particularly for TaqMan undetectable (57%) and <15 IU/ml (32%; Table 3 and Figure 1B ).
Discussion
Current recommendations for the treatment of HCV genotype 1 patients with PEG-IFN and RBV include measurement of viral load at week 24 of therapy and to cease treatment for futility in patients with detectable HCV RNA [13] . However, the development of new and more sensitive quantitative HCV RNA assays has led to an increasing number of patients being observed with low residual viraemia at treatment week 24 who previously recorded an undetectable viral load using qualitative PCR assays, such as Amplicor. Until now, information was limited on the relevance of low residual viraemia during treatment on long-term virological outcomes in these patients or of the appropriateness of the current week 24 stopping rule in the era of real-time PCR assays. In this study we evaluated the utility of the sensitive TaqMan HCV RNA assay for on-treatment clinical guidance, and specifically the detection of low-level residual viraemia at week 24 as a predictor of virological relapse or breakthrough, in a large cohort of HCV genotype-1-infected patients undergoing PEG-IFN/RBV therapy. The main study finding was that the SVR rate was significantly lower and the virological relapse or breakthrough rate significantly higher in patients with low residual viraemia (detectable <50 IU/ ml) compared to those with undetectable HCV RNA at week 24. However, the likelihood of an SVR based on PPV is only marginally reduced when an HCV RNA cutoff of <15 IU/ml (that is, including undetectable and detectable <15 IU/ml HCV RNA) is used compared with a cutoff of undetectable HCV RNA at week 24 ( Figure 1 ). We also demonstrated that the overall agreement between the TaqMan and Amplicor assays is better using TaqMan cutoffs of <15 IU/ml or <50 IU/ml compared to TaqMan undetectable. These results provide important new insights into our understanding of the adverse impact of low-level viraemia on long-term virological outcomes in HCV genotype 1 patients undergoing PEG-IFN and RBV treatment.
A key observation from our study was that the enhanced sensitivity of the TaqMan assay produces considerable heterogeneity in treatment response rates based on different low HCV viraemia strata at week 24: namely, HCV RNA undetectable, detectable <15 IU/ml and 15-50 IU/ml. Two-thirds of patients in the CHARIOT study had a TaqMan undetectable result at week 24 and, among those, 72% achieved an SVR. By comparison, among the 7% of patients with minimal residual viraemia (detectable <15 IU/ml), an SVR was achieved in 17 of 59 (29%) patients. Finally, in the small (approximately 1%) proportion of patients with detectable low-level viraemia (15-<50 IU/ml), only 1 of 7 (14%) patients achieved an SVR ( Figure 1A) . Gerotto et al. [11] reported a similar differential response rate in a heterogeneous cohort of chronic hepatitis C patients undergoing treatment with PEG-IFN-α2b plus RBV. In that study, 22 of 26 (96%) chronic hepatitis C patients with minimal residual viraemia at the end of therapy, defined as a positive test by the highly sensitive TMA assay (LOD 10 IU/ml) but negative by conventional PCR, failed to maintain their response during follow-up compared to only 14% of TMA-negative patients [11] . Similarly, Matsuura et al. [12] noted, in a small cohort of patients, that minimal residual viraemia by the TaqMan assay at the end of therapy was associated with relapse during post-treatment follow up. These results emphasize the importance of having an undetectable viral load on therapy in achieving long-term HCV clearance.
The low SVR rate observed in patients with lowlevel viraemia at week 24 was due in part to the high frequency with which virological relapse or breakthrough occurred prior to week 72. Notably, relapse/ breakthrough occurred in 48 of 66 (73%) patients with HCV RNA detectable <50 IU/ml at week 24, including 42 of 59 (71%) patients with detectable <15 IU/ ml and 6 of 7 (86%) of patients with HCV RNA levels 15-<50 IU/ml, compared to only 156 of 563 (28%) patients with TaqMan undetectable at week 24 (Figure 1A) . How then can treatment be further optimized for patients with low residual viraemia at week 24 in order to enhance SVR rates? Treatment for up to 72 weeks has been shown to improve SVR outcomes in HCV genotype 1 patients who have slow EVRs to treatment [22] [23] [24] . Sanchez-Tapias et al. [22] demonstrated that extending therapy with PEG-IFN plus RBV to 72 weeks in non-virological responders at week 4 resulted in higher SVR rates and lower relapse rates compared to patients treated for 48 weeks, while Berg et al. [23] demonstrated similar findings in a subset of patients who failed to achieve a virological response at week 12. More recently, Ferenci et al. [24] demonstrated the benefit of an extended 72 week treatment course in a cohort of HCV genotype 1-or 4-infected patients who achieved an EVR but not a week 4 response. Although the approaching era of direct acting antiviral agents makes it unlikely that clinical studies will be conducted to test a similar strategy in residual viraemic patients at week 24, it is not unreasonable to consider extending PEG-IFN/RBV treatment beyond week 48 in the interim in such patients. This strategy should be coupled with close HCV RNA monitoring using a sensitive detection assay (LOD 10-15 IU/ml) until viral eradication is achieved.
Our data also raise concerns that the current 24-week stopping rule criterion to discontinue treatment in patients with detectable HCV RNA might be too stringent in the context of using highly sensitive PCR assays. Indeed we found 29% of patients with detectable HCV RNA levels <15 IU/ml at week 24 achieved an SVR but that only 1 of 7 patients with HCV RNA levels between 15-50 IU/ml maintained their response long term. More importantly, the NPV for SVR of a week 24 viral response defined by undetectable HCV RNA was only 86%; this is lower than the 100% NPV reported by Matsuura et al. [12] using the same assay and cutoff. In contrast, we found the NPV was higher at 90% when HCV RNA thresholds of either <15 IU/ml and <50 IU/ml were used to define virological response. Taken in combination, these data suggest that recommendations to cease treatment with PEG-IFN plus RBV at week 24 for futility should be based on an HCV RNA cutoff <15 IU/ml rather than undetectable when utilizing sensitive assays like TaqMan to monitor viral response. However, as this study evaluated only one assay and because differences might exist between highly sensitive assays in the predictability of SVR to PEG-IFN-based therapy [12] , further and preferably comparative studies (for example, with the Abbott RealTime assay) are needed to validate these findings prior to the broad adoption of this recommendation.
The results of the 'agreement' analysis between TaqMan and Amplicor on low residual viraemia samples have important clinical implications for the monitoring of virological response and outcomes of responseguided therapy. In particular, 33% of samples with minimal residual viraemia (detectable <15 IU/ml) by TaqMan at week 24 tested positive by Amplicor that included 19 of 129 (15%) of TaqMan-negative samples at a cutoff <15 IU/ml. This suggests that the use of less sensitive qualitative assays, such as Amplicor, to monitor virological response might lead to the inappropriate discontinuation of treatment at week 24 in some patients who might otherwise achieve an SVR. Conversely, we found that 7 of 22 samples (32%) with a positive TaqMan test at cutoff of <15 IU/ml (that is, HCV RNA≥15 IU/ml) were negative by Amplicor. In this case, the use of Amplicor alone to monitor response could result in an unnecessary extension of therapy beyond week 24 in some patients who otherwise have a low likelihood of an SVR.
An important issue raised by the above is whether highly sensitive quantitative HCV assays like TaqMan can replace the Amplicor qualitative test to monitor virological response. Central to addressing this are the data on treatment outcomes in patients with detectable HCV RNA levels <15 IU/ml and <50 IU/ml at week 24, and the PPV and NPV for SVR and percentage agreement between the TaqMan and Amplicor assays at the different RNA cutoffs. In particular, patients with minimal residual viraemia <15 IU/ml appeared to respond more like Amplicor-negative than -positive patients, while the poor SVR observed in those with low-level viraemia 15-49 IU/ml was similar to that observed by our group and others in Amplicor-positive patients ( Figure 1A ) [1, 3, 17] . In addition, the PPV and NPV for SVR using a week-24 cutoff <15 IU/ml or <50 IU/ml was closely related to that observed in Amplicor-negative patients ( Figure 1A) . Also, the overall agreement between Amplicor and TaqMan was better for a TaqMan cutoff of 15 IU/ml or 50 IU/ml compared to TaqMan undetectable, with the best sensitivity and specificity for agreement being for a cutoff <50 IU/ml. Together, these data suggest that from a clinical perspective the TaqMan assay can also function as a surrogate qualitative test to monitor virological response with a TaqMan result <15 IU/ ml appearing to be comparable to an Amplicor negative (<50 IU/ml) result ( Figure 1A and 1B) .
In conclusion, this study demonstrates that patients with detectable low residual viraemia (<50 IU/ml) at week 24 have significantly lower SVR and higher relapse rates than patients with undetectable HCV RNA. While these data emphasize the importance of achieving undetectable RNA at week 24, the current 24-week stopping rule of HCV RNA undetectable appears too stringent when using sensitive HCV RNA assays like TaqMan based on the observed lower NPV for SVR for this viral load cutoff. Our data also suggest that a TaqMan <15 IU/ml result is comparable overall to an Amplicor-negative result when monitoring viral response.
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